Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Buprenorphine Header

    Virtual Booth

    Contact Supplier

    Buprenorphine

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    SCI PHARMTECH Buprenorphine

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Buprenorphine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,193Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Purdue Expands Low-Cost Opioid Disorder Treatment to Prisons
    Purdue Expands Low-Cost Opioid Disorder Treatment to Prisons

    02 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250902734627/en/Purdue-Pharma-L.P.-Expands-its-Provision-of-Low-Cost-Opioid-Use-Disorder-Treatment-to-Correctional-Facilities-for-Incarcerated-Individuals

    BUSINESSWIRE
    02 Sep 2025
    Share Share
    Akyso Gets NIH Grant for Buprenorphine Implant After Trial
    Akyso Gets NIH Grant for Buprenorphine Implant After Trial

    05 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250729152776/en/Akyso-Therapeutics-Expands-Pipeline-with-New-NIH-Grant-for-Buprenorphine-Implant-Following-Successful-Phase-1a-Trial-of-Naltrexone-Implant

    BUSINESSWIRE
    05 Aug 2025
    Share Share
    Indivior Data Shows High Buprenorphine May Aid Fentanyl Users
    Indivior Data Shows High Buprenorphine May Aid Fentanyl Users

    19 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-presents-new-data-at-cpdd-demonstrating-that-high-buprenorphine-exposure-may-improve-treatment-outcomes-in-high-fentanyl-users-302486036.html

    PR NEWSWIRE
    19 Jun 2025
    Share Share
    Study: Monthly Subloclade® for Opioid Use Disorder in Pregnancy
    Study: Monthly Subloclade® for Opioid Use Disorder in Pregnancy

    01 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-study-highlights-monthly-sublocade-as-a-potential-treatment-option-for-opioid-use-disorder-during-and-after-pregnancy-302444173.html

    PR NEWSWIRE
    01 May 2025
    Share Share
    Amid market headwinds, Indivior's Sublocade gains FDA nod
    Amid market headwinds, Indivior's Sublocade gains FDA nod

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-release-injection-302382920.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    Indivior Announces FDA Approval of Label Changes for Sublocade
    Indivior Announces FDA Approval of Label Changes for Sublocade

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-release-injection-302382920.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share